介入放射学在临床试验团队中的价值:来自BATTLE肺癌试验的经验
该研究回顾了BATTLE和BATTLE-2试验中经皮影像引导活检的555例患者,开发了基于影像的三分病灶评分系统并由两位介入放射科医生(IR)使用。总体生物标志物分析取材充分率为86.1%(478/555),评分3分病灶的充分率为89%,评分2分且有两个以上不利因素的病灶充分率分别为69.2%(IR1)和74%(IR2)。结论认为IR通过优化活检病灶选择为临床试验团队增加价值。
要点
- 总分3分病灶(大小>2cm、实性、有活性影像证据、技术易取样)生物标志物分析充分率达89%。
- 总分2分且存在两个以上不利因素的病灶充分率分别为69.2%(IR1)和74%(IR2)。
- 两位IR对78.4%的病灶评分一致,一致性中等(kappa=0.55;95%CI:0.48,0.61)。
关键影像表现/征象
- 评分3分病灶需满足大小>2cm、实性肿块、有影像学活性证据且技术易于取样四项标准。
- 未满足全部四项标准的病灶评为2分,并记录缺失标准为不利因素。
- 风险大于潜在获益的病灶评为1分且未进行活检。
诊断标准与关键数值
- 总体生物标志物分析取材充分率为86.1%(478/555)。
- BATTLE试验取材充分率为84%(268/319),BATTLE-2试验为88.9%(210/236),两者比较p=0.09。
- 评分3分病灶的生物标志物分析充分率为89%。
- 评分2分且有两个以上不利因素的病灶,分子分析充分率分别为69.2%(IR1,p=0.03)和74%(IR2,p=0.04)。
- 两位IR评分一致率为78.4%,一致性中等(kappa=0.55;95%CI:0.48,0.61)。
临床应用与阅片要点
- 介入放射科医生使用三分病灶评分系统选择活检病灶,可能有助于优化临床试验中的生物标志物取材。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To report on the multidisciplinary approach, focusing specifically on the role of the interventional radiologist (IR), used to support the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) and BATTLE-2 trials.
MATERIALS AND METHODS: Patients who underwent percutaneous image-guided biopsy for the BATTLE and BATTLE-2 trials were reviewed. A radiology-based, three-point, lesion-scoring system was developed and used by two IRs. Lesions were given a score of 3 (most likely to yield sufficient material for biomarker analysis) if they met the following criteria: size >2 cm, solid mass, demonstrated imaging evidence of viability, and were technically easy to sample. Lesions not meeting all four criteria were scored 2 with the missing criteria noted as negative factors. Lesions considered to have risks that outweighed potential benefits receive a score of 1 and were not biopsied. Univariate and multivariate analyses were performed to evaluate the score's ability to predict successful yield for biomarker adequacy.
RESULTS: A total of 555 biopsies were performed. The overall yield for analysis of the required biomarkers was 86.1% (478/555), and 84% (268/319) and 88.9% (210/236) for BATTLE and BATTLE-2, respectively (p=0.09). Lesions receiving a score of 3 were adequate for biomarker analysis in 89% of cases. Lesions receiving a score of 2 with more than two negative factors were adequate for molecular analysis in 69.2% (IR1, p=0.03) and 74% (IR2, p=0.04) of cases. The two IRs scored 78.4% of the lesions the same indicating moderate agreement (kappa=0.55; 95% confidence interval [CI]: 0.48, 0.61).
CONCLUSIONS: IRs add value to clinical trial teams by optimising lesions selected for biopsy and biomarker analysis.
引用
- Tam AL, Papadimitrakopoulou V, Wistuba II, et al. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol. 2020. PMID: 33268083. doi:10.1016/j.crad.2020.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。